INTRODUCTION
It has been postulated that adrenergic receptors are linked to the adenylate cyclase-cyclic AMP system (1) . According to this hypothesis an effective interaction of a catecholamine with beta adrenergic receptors causes activation of adenylate cyclase, an increase in cyclic AMP, and an increase in hormone response, while interaction with alpha sites reduces the effective concentration of cyclic AMP leading to an opposite effect on cell function. We have recently tested this hypothesis with a homogenous cell system consisting of human adipocytes, and our findings agreed closely with those predicted by the hypothesis (2, 3) . Obviously, the significance of these observations would be enhanced if similar findings were made in the intact human. The in vivo demonstration of alpha site activity in adipose tissue is complicated by the fact that adrenergic agonists and blockers have widespread effects. Particularly troublesome is the influence of catecholamines on the secretion of insulin, a potent Portions of this report were presented at the Southern Society for Clinical Investigation, 28 January 1973, New Orleans. antilipolytic hormone. The effects of catecholamines on the cardiovascular system might also obscure or distort metabolic responses. In an attempt to circumvent or minimize these problems, two approaches were used as described below.
METHODS Experimental design I. The first approach (see Fig. 1 ) depended on the absence of regulated insulin secretion. A 20-yr-old man who had undergone a total pancreatectomy a year earlier for an islet cell adenoma located immediatley adjacent to the duodenum was studied over an 8-day period. The subj ect's acquired diabetes was reasonably well controlled and other than an occasional loose stool, he had no complaints and appeared to be in good health. On days 2 and 6, propranolol was administered; on day 4 and 8, phentolamine was given; no experiments were done on days 1, 3, 5, and 7. On each experimental day, the patient fasted, and his insulin was withheld until after the study was completed. Each study consisted of four 60-min periods. Initially, saline was infused (period I). This was followed by either propranolol, 0.08 mg/min or by phentolamine, 0.5 mg/min (periods II and III); finally epinephrine was infused at a rate of 6 ,ug/min (periods III and IV). The blockers and epinephrine were obtained frorn commercial sources; the doses used had been administered without difficulty by Porte (4 was then commenced and infused at a constant rate through periods II, III, IV, and V. In a third series of experiments, saline was continued through period II and no blocker was administered. Epinephrine was started at the outset of period III at a rate of 0.25 jig/min. This was increased to 0.5 jug/min at the beginning of period IV, and then to 1 jig/min (period V). Blood pressure and pulse 'were determined every 15 min, and blood was obtained for the estimation of free fatty acids, glycerol (6), glucase, and insulin (7) .
All subjects studied were hospitalized on the ward of the Clinical Research Center. The protocols followed were approved by the institution's Committee for Projects In- (8) .
RESULTS Experimental design I. During the infusion of saline, propranolol, phentolamine, and the combination of propranolol and epinephrine (period III) the subject was free of symptoms. However, during the administration of epinephrine and phentolamine, the patient was anxious and developed palpitation and mild muscular twitching. Midway during the second phentolamine experiment, the patient complained of chest discomfort and the study was terminated. Except for change in rate, continuous monitoring of the electrocardiograph revealed no changes during any of the four studies.
FFA results expressed as a percent change from the mean of control values are contained in Fig. 1 In the presence of propranolol, the lowest infusion rate of epinephrine caused a modest increase in diastolic blood pressure; during the highest infusion rate this increase was statistically significant (period I vs. V, P < 0.01). In the presence of phentolamine, epinephrine prompted a small but significant decline in blood pressure (period I vs. III, P <0.01). The latter effect became more marked with higher doses of epinephrine. Changes comparable in degree but opposite in direction were noted in the pulse. Thus, while the lowest infusion rate of epinephrine used in these experiments, 0.25 Ag/min, was sufficient, in the face of adrenergic blockade, to alter diastolic blood pressure and pulse, these changes were relatively small compared to those noted in FFA concentration.
The plasma glucose concentration remained unchanged throughout the infusion of the epinephrine-plus-phentolamine combination; during the infusion of epinephrine alone and of epinephrine plus propranolol, it gradually rose. The glucose concentrations in period V were statistically significantly higher than those of period I. The P values for epinephrine alone and for epinephrine pllts propranolol were each < 0.01 (data not shown).
DISCUSSION The results obtained with both experimental design I and II suggest that both alpha and beta adrenergic receptor sites are present in human adipose tissue. When alpha sites are blocked, as during phentolamine administration, the stimulation of beta sites by endogenous catecholamines is unopposed and the level of plasma FFA increases. This effect is substantially enhanced by the administration of epinephrine. When beta sites are blocked, as during propranolol infusion, lipolysis declines and the plasma concentration of FFA tends to fall below the control level. In the pancreatectomized subject this fall was accentuated by the infusion of epinephrine, suggesting that negative alpha sites were being stimulated (experimental design I, Fig. 1 ). The fact that this accentuation was not observed in normal subjects (experimental design II, Fig. 2 (10) have presented evidence indicating the existence of both alpha and beta sites in rat parotid gland tissue; the former prompted release of potassium ion while the latter stimulated amylase secretion. Propranolol had no effect on the alpha adrenergic response, suggesting that the alpha receptor response in this tissue is not related to cyclic AMP.
If we assume that both beta and alpha adrenergic receptors are present in human adipose tissue, basic questions remain unanswered. Does alpha site stimulation reduce cyclic AMP by inhibiting adenylate cyclase by stimulating phosphodiesterase, or by some other mechanism? More fundamental questions concern the survival value that dual adrenergic sites had primitive man, and the physiological advantage, if any, of such a system to modern man. Of interest are the recent studies of Rosen-quist (11) demonstrating that adipose tissue from hypothyroid patients fails to respond to the lipolytic action of epinephrine; this effect was not due to impaired beta site activity, but rather to enhanced alpha adrenergic responsiveness.
Of several other species (rat, swine, dogs, rhesus monkey, guinea pig, and hamster) whose adipose tissue we have tested for alpha site activity,. only two, the ham-.ster and monkey, were found to have both beta and alpha receptors.
